Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 1.00 |
| ▸ | KDM1A | O60341 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 6/20 | 0.52 |
| ▸ | HTR2A | P28223 | 5/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137817 | 1.00 | HTR2C (1.00) | HTR2CKDM1AMAOAHTR2BHTR2A | |
| SCHEMBL27506165 | 0.89 | HTR2C (0.79) | HTR2CKDM1AMAOAHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL6416841 | 0.88 | HTR2C (0.77) | HTR2CKDM1AMAOAHTR2BHTR2A | |
| SCHEMBL16507112 | 0.81 | HTR2C (0.66) | HTR2CKDM1AMAOAMAOBMEN1 | |
| SCHEMBL16507114 | 0.81 | HTR2C (0.66) | HTR2CKDM1AMAOAMAOBMEN1 | |
| SCHEMBL14498489 | 0.80 | HTR2C (0.67) | HTR2CKDM1AMAOAHTR2AMAOB | |
| SCHEMBL12512197 | 0.80 | HTR2C (0.68) | HTR2CKDM1AHTR2BHTR2AMAOB | |
| SCHEMBL14568843 | 0.79 | HTR2C (1.00) | HTR2CKDM1AMAOAHTR2BHTR2A | |
| SCHEMBL6337289 | 0.79 | HTR2C (1.00) | HTR2CKDM1AMAOAHTR2BHTR2A | |
| SCHEMBL4139467 | 0.79 | HTR2C (1.00) | HTR2CKDM1AMAOAHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | HTR2C 4102/4885KDM1A 1628/4885MAOA 1147/4885 |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | HTR2C, HTR2A, HTR5A | HTR2C 1/4885KDM1A 3105/4885MAOA 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.